Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Weleader Biomedical CoROCO:7713 +1.58%42 Receivables Turnover is 0.93 as of Mar. 2026. GuruFocus rates ROCO:7713 with a GF Score™ of 42/100. The stock has 5 warning signs investors should review. Among 813 Medical Devices & Instruments companies, Weleader Biomedical Co ranks worse than 74.91% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Weleader Biomedical Co's Revenue for the
three
months ended in Mar. 2026 was NT$279 Mil. Weleader Biomedical Co's average Accounts Receivable for the
three
months ended in Mar. 2026 was NT$300 Mil.
Hence, Weleader Biomedical Co's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.93.
Weleader Biomedical Co (ROCO:7713) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Weleader Biomedical Co Receivables Turnover Related Terms
Weleader Biomedical Co Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Weleader Biomedical Co's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7713 vs ABT, SYK, MDT: Receivables Turnover Comparison
For the Medical Devices subindustry, Weleader Biomedical Co's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Weleader Biomedical Co Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Weleader Biomedical Co's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Weleader Biomedical Co's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Weleader Biomedical Co (ROCO:7713) has a Receivables Turnover of 0.93 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Weleader Biomedical Co and its competitors. According to the industry distribution chart, Weleader Biomedical Co ranks #609 out of 813 companies in the Medical Devices & Instruments industry, placing it in the top 74.9%.
Is Weleader Biomedical Co's Receivables Turnover too high?
Weleader Biomedical Co's current Receivables Turnover is 0.93. The Medical Devices & Instruments industry median Receivables Turnover is 5.60. Weleader Biomedical Co's value of 0.93 is 83.4% below this industry median. Based on the distribution chart, Weleader Biomedical Co ranks #609 out of 813 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Weleader Biomedical Co has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does Weleader Biomedical Co's Receivables Turnover compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Weleader Biomedical Co ranks #609 out of 813 companies for Receivables Turnover. This places Weleader Biomedical Co in the lower half of its industry. The industry median Receivables Turnover is 5.60. Weleader Biomedical Co's value of 0.93 is 83.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.60, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Weleader Biomedical Co's current Receivables Turnover of 0.93 is 83.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Weleader Biomedical Co and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Weleader Biomedical Co's current Receivables Turnover is 0.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Weleader Biomedical Co stock overvalued right now?
Weleader Biomedical Co (ROCO:7713) has a current Receivables Turnover of 0.93. The current Receivables Turnover is 0.93 and 83.4% below the Medical Devices & Instruments industry median of 5.60. Weleader Biomedical Co's overall GF Score™ is 42/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Weleader Biomedical Co (ROCO:7713), the current Receivables Turnover is 0.93 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Weleader Biomedical Co Ltd is mainly engages in the sales of medical testing reagents and medical devices; and the leasing of testing instruments. The reportable segments of the Group are: The Company, which includes sale of testing reagents, and provision of testing instruments and services; and Health Leader, which includes sale of dietary supplements and testing reagents, and provision of information and professional services. It derives majority revenue from the Company segment. Geographically, the company operates and generates revenue from Taiwan.
42GF Score
Get the complete analysis for ROCO:7713
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7713 has been successfully added to your 
